

RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.

CIN: L24232MH2007PLC169354;

Tel: +91-22-24981650; Fax: +91-22-24970127

E-mail: info@rpglifesciences.com; Web: www.rpglifesciences.com



PART I (Rs. in lakhs)
STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30th JUNE, 2014

PARTICULARS	3 months ended			Year ended
	30.6.2014	31.3.2014	30.6.2013	31.3.2014
	Unaudited			Audited
1. Income from Operations				
(a) Net Sales/Income from Operations (Net of Excise Duty)	5,879	5,114	6,290	22,938
(b) Other Operating Income	77	160	128	595
Total Income from Operations (Net)	5,956	5,274	6,418	23,533
2. Expenses				
(a) Cost of Materials Consumed	1,526	1,342	1,910	6,581
(b) Purchases of Stock-in-Trade	516	370	449	1,943
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	233	128	(350)	(849)
(d) Employee Benefits Expense	1,561	1,496	1,472	6,218
(e) Depreciation and Amortisation Expense (including prior period credit of Rs. 56 lakhs) [Refer Notes 4 and 5]	226	273	254	1,061
(f) Provision for Doubtful Debts and Advances (Net)	9	(28)	15	689
(g) Other Expenses	1,765	1,748	2,080	7,805
Total Expenses	5,836	5,329	5,830	23,448
3. Profit/(Loss) from Operations before Other Income, Finance Costs and Exceptional Items	120	(55)	588	85
4. Other Income	32	40	84	258
5. Profit/(Loss) from Ordinary Activities before Finance Costs and Exceptional Items	152	(15)	672	343
6. Finance Costs	42	39	161	260
7. Profit/(Loss) from Ordinary Activities after Finance Costs but before Exceptional Items	110	(54)	511	83
8. Exceptional Items	-	(12)	6,426	6,414
9. Profit/(Loss) from Ordinary Activities before Tax	110	(66)	6,937	6,497
10. Tax Expense/(Credit) (including Deferred Tax)	(6)	(15)	1,468	1,157
11. Net Profit/(Loss) for the period	116	(51)	5,469	5,340
12. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323
13. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)				11,253
14. Earnings/(Loss) per Share (of Rs. 8 each) (not annualised):				
(a) Basic	0.70	(0.31)	33.07	32.29
(b) Diluted	0.70	(0.31)	33.07	32.29

PART II

Select Information for the Quarter ended 30th June, 2014

PARTICULARS	3 months ended			Year ended
	30.6.2014	31.3.2014	30.6.2013	31.3.2014
A PARTICULARS OF SHAREHOLDING				
1. Public Shareholding				
- Number of Shares	6,321,501	6,380,451	7,196,344	6,380,451
- Percentage of Shareholding	38.23	38.59	43.52	38.59
2. Promoters and Promoter Group Shareholding				
(a) Pledged/Encumbered				
- Number of Shares	-	-	-	-
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-
- Percentage of Shares (as a % of the total Share Capital of the company)	-	-	-	-
(b) Non-Encumbered				
- Number of Shares	10,213,740	10,154,790	9,338,897	10,154,790
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total Share Capital of the company)	61.77	61.41	56.48	61.41

PARTICULARS	3 months ended 30.06.2014
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	6
Disposed of during the quarter	6
Remaining unresolved during the quarter	-

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 23rd July, 2014 and 24th July, 2014 respectively.
- The results for the quarter ended 30th June, 2014 have been subjected to limited review by the statutory auditors of the Company.
- The Company is exclusively engaged in the pharmaceuticals segment.
- Pursuant to the enactment of the Companies Act, 2013, effective 1st April, 2014, the management has evaluated and reassessed the useful life of its fixed assets. Consequent to such change, the charge on account of depreciation for the quarter is higher by Rs. 11 lakhs. Further, fixed assets of Rs. 1 lakh having no residual life as at 1st April, 2014, have been recognised in the opening balance of General Reserve.
- Depreciation expense for the quarter ended 30th June, 2014 includes prior period credit of Rs. 56 lakhs representing impact of rectification in the classification and estimated useful life of certain fixed assets.
- Figures for the prior periods have been regrouped where necessary.

For **RPG Life Sciences Limited**

Ajit Singh Chouhan
Managing Director

Mumbai, 24th July, 2014

